Compared with commonly defined risk factors in the AML-BFM studies, flow cytometry does not provide additional information for outcome prediction, but may be helpful to evaluate the remission status ...

Flow Cytometry Indicates Treatment Response in AML For children with acute myeloid leukemia (AML), minimal residual disease (MRD) activity, as measured using flow cytometry, is a good indicator of ...

Flow MRD, also offering a high ... Bone marrow samples from patients with AML (excluding patients with acute promyelocytic leukemia) were analyzed by flow cytometry between 2000 and 2011 within ...

Among patients with AML, the detection of molecular minimal residual disease during complete ... Detection of residual disease with multiparameter flow cytometry was performed as described previously.

Measurable residual disease (MRD) can predict disease progression in patients who have acute myeloid leukemia (AML ... to perform MRD assessment: multiparameter flow-cytometry (MFC), quantitative ...

A recent study described the use of multiparameter flow cytometry (MFC) to detect minimal residual disease (MRD), with an 8-color flow cytometric method with a 10 5 sensitivity, using monoclonal ...

Multiparametric flow cytometry assays are widely used in detecting ... and evaluating measurable residual disease (MRD) in AML samples. The new panel unleashes the power of Cytek’s Full Spectrum ...

Disease relapse is a common cause of treatment failure after allogeneic HSCT (allo-HSCT) for patients with acute leukemia. MRD identified through multiparameter flow cytometry serves as a strong ...

NewsVoir New Delhi [India], June 16: To achieve a consensus on a suitable panel and analysis strategy to report Acute Myeloid Leukemia - Measurable Residual Disease (AML-MRD) by flow cytometry, BD ...

Included among the presentations is the first data demonstrating the potential actionability of Mission Bio’s Tapestri® Single-Cell MRD ... and multiparameter flow cytometry (MFC), in AML ...

Compared with commonly defined risk factors in the AML-BFM studies, flow cytometry does not provide additional information for outcome prediction, but may be helpful to evaluate the remission status ...